CRO reputation vital when selecting outsourcing partner; CEO

By Nick Taylor

- Last updated on GMT

Related tags: Contract research organization

Outsourcing to a well known CRO with a good reputation is vital to ensuring that data is well received by regulatory authorities, according to a CEO that just inked a deal for preclinical safety testing.

Speaking to Outsourcing-Pharma Rami Efrati, CEO of BrainStorm Cell Therapeutics, explained that his business will only outsource to well known companies because of the benefits they bring.

According to Efrati trials conducted at a well known and reputable contract research organisation (CRO) will be better received by regulatory authorities, which is an important factor for BrainStorm as it prepares to enter clinical trials.

BrainStorm has contracted Harlan Biotech Israel (HBI) to conduct safety trials of its amyotrophic lateral sclerosis in mice in preparation for applying to the Israeli Ministry of Health to conduct Phase I.

The decision to outsource was motivated by a lack of in-house capacity but Efrati added that even if BrainStorm had the capabilities he would have used a CRO.

This is in part motivated by the perceived benefits with regulatory agencies but also because Efrati believes there are advantages to having external personnel view the product and data.

Further outsourcing

The deal with HBI was preceded by a contract manufacturing deal with Protein Production Services (PPS), which will provide materials for the preclinical safety trial.

BrainStorm entered into the two contracts after it received funding from the Israeli government’s Office of the Chief Scientist and from a private investor, which enabled the company to commence the final preclinical steps.

Once this is complete BrainStorm intends to enter Phase I trials and Efrati said that further outsourcing will be needed at this stage. He explained that BrainStorm lacks the capacity to do clinical trials or manufacture current good manufacturing practice (cGMP) compliant materials.

Related news

Show more

Related products

show more

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Planning Your Preclinical Assessment

Planning Your Preclinical Assessment

Altasciences | 17-Jan-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 17-Jan-2022 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Related suppliers

Follow us

Products

View more

Webinars